AMCP Annual Meeting 2017

Satellite Symposia


The following listing is provided to you by the Academy of Managed Care Pharmacy as a courtesy; these non-commercial industry-supported Satellite Symposia activities are not part of the AMCP Managed Care & Specialty Pharmacy Annual Meeting programming, but they are an important part of our meeting and are planned to meet the same standards of continuing quality education. Satellite Symposia offer continuing pharmacy education (CPE) credit—some also offer continuing medical education (CME) credit, continuing nursing education (CNE) credit, or all three. Satellite Symposia in conjunction with the AMCP Annual Meeting 2017 are held at the Colorado Convention Center in Denver, Colorado. Any pre-registration taken for these activities is for planning purposes only and does not guarantee a seat. Seating is limited and provided on a first-come, first-served basis. An early arrival is recommended. For additional information about a specific symposium please contact the program manager listed.



MONDAY, MARCH 27
Monday, March 27
6:00 PM – 8:00 PM
The Specialty Pharmacy Review Board™ – Assessing the Value of Novel Therapies and Care Management Strategies for Multiple Sclerosis

Provided by Impact Education, LLC and Medical Education Resources, Inc.
Supported by an independent educational grant from Novartis Pharmaceuticals Corporation


Continuing education credit available for pharmacists and physicians.

Program Description
Multiple sclerosis (MS) is a complex disease that requires a collaborative approach to care to achieve optimal patient care and outcomes. Disease-modifying therapies (DMTs) are a core component of MS management. Given current constraints on health care expenditures, the relative cost-effectiveness of these therapies needs to be considered when making treatment decisions. Due to a lack of head to head trials it is difficult to determine which therapy would be most effective for MS; however, it is possible to evaluate current therapies based on their effects on sustained disability, relapse rate, lesion load, brain atrophy, and cognitive dysfunction. Members of the clinical team, as well as patients, need to coordinate these efforts when choosing the appropriate therapy and continually monitor the disease, manage symptoms and the psychological aspects of the disease, and engage the patient through coordinated patient education in order to achieve optimal clinical, economic, and humanistic outcomes. Therefore, it is important for specialty pharmacists and managed care professionals to be aware of and engaged in the care and treatment of MS patients. This symposium will provide an update on available treatments, best practices in care coordination among multiple stakeholders, and benefit design considerations to optimize patient outcomes.

The educational format of The Specialty Pharmacy Review Board will feature a multi-specialty, multi-professional faculty that collaborate, under the leadership of an Activity Chair, on the review of the clinical data, current guidelines, and economic data of a class of therapeutics. Similar to a mock pharmacy and therapeutics committee format, the program will include time for peer-to-peer discussion and debate among the diverse group of faculty members and the audience.

Program Manager
Steven Casebeer, MBA
Impact Education, LLC
info@impactedu.net
215-619-8812, extension 102

No Fee Registration: Click Here
TUESDAY, MARCH 28
Tuesday, March 28
6:00 AM – 8:00 AM
Treatment Options, Comparative Effectiveness, and Coordinated Care: A Psoriatic Disease Update for Managed Care and Specialty Pharmacy

Provided by Impact Education, LLC and Annenberg Center for Health Sciences at Eisenhower
Supported by independent educational grants from Celgene Corporation and Novartis Pharmaceuticals Corporation


Continuing education credit available for pharmacists and physicians.

Program Description
Psoriasis is one of the most common autoimmune diseases to develop in genetically susceptible individuals with an estimated 7.5 million Americans afflicted by psoriasis; and psoriatic arthritis is considered to be one of the most disabling types of arthritis affecting as many as 2.3 million Americans. Direct annual health care costs assigned to the management of psoriatic disease is estimated to be as high as $2.0-3.0 billion. As novel agents become available, treatment decision making is becoming more complex and managed care professionals need to appropriately and effectively design benefits that optimize both cost-efficiency and patient outcomes.

The expert faculty panel will present the latest clinical data to recommend appropriate therapies, utilize comparative effectiveness research (CER), design appropriate medical and pharmacy benefits, and implement health care quality measures. Emerging clinical and economic techniques, practical examples, and expert recommendations will be formulated to illuminate key learnings using psoriatic disease as the therapeutic area of focus.

Program Manager
Steven Casebeer, MBA
Impact Education, LLC
info@impactedu.net
215-619-8812, extension 102

No Fee Registration: Click Here

Tuesday, March 28
6:00 AM – 8:00 AM
Late-Breaking Updates and New Targets in the Therapeutic Landscape for Adults with Atopic Dermatitis

Provided by PRIME Education, LLC.
Supported by an independent educational grant from Genzyme, a Sanofi Company and Regeneron Pharmaceuticals


Continuing education credit available for pharmacists, physicians and nurses.

Program Description
Is your organization prepared for game-changing advances in the treatment of atopic dermatitis (AD)? A growing body of knowledge on the immune-mediated drivers of AD has led to the development of targeted therapies that are showing unprecedented success in the safe and effective treatment of moderate-to-severe AD. Join the discussion and pose your questions to a leading panel of experts in dermatology, allergy, immunology, and managed care as they help translate evidence to practice and identify key considerations for managed care decision-makers in the midst of changing paradigms. This day-break symposium is designed to support organizations as they gather data and begin to discuss policy issues related to future patient benefit designs impacting access to AD therapy, including tiering, co-pays, and other issues related to benefit/risk of new therapies.

Program Manager
Samantha Hoffman
PRIME Education, LLC
s.hoffman@primeinc.org
954-718-6055

No Fee Registration: Click Here
WEDNESDAY, MARCH 29
Wednesday, March 29
6:00 AM – 8:00 AM
The Specialty Pharmacy Review Board™ – Examining Emerging Therapies and Care Management Intervention for Alzheimer’s Disease

Provided by Impact Education, LLC and Medical Education Resources, Inc.
Supported by independent educational grants from Avanir Pharmaceuticals, Inc. and Lilly USA, LLC. For further information concerning Lilly grant funding visit www.LillyGrantOffice.com.


Continuing education credit available for pharmacists and physicians.

Program Description
Alzheimer’s disease (AD) represents a significant driver of morbidity and mortality in the US, despite being overshadowed by other predominant conditions for which more effective treatment modalities exist. The incidence and mortality associated with the disease is increasing, indicating a key area of concern for managed care stakeholders. An estimated 5.3 million Americans were living with AD in 2015, and as many as 7.1 million will be diagnosed with the disease by 2025 according to the Alzheimer's Association. By 2050, that number may nearly triple to a projected 13.8 million, barring the development of medical breakthroughs to prevent or cure the disease. Unsurprisingly, this considerable burden of illness associated with AD is also accompanied by extensive direct and indirect costs.

This symposium will feature a multidisciplinary faculty panel who will present best practices for implementing collaborative treatment and patient management decisions that lead to optimal outcomes for patients with AD. This approach will enhance the audiences’ ability to recommend and implement payer specific techniques to improve the continuity of care related to the impact of AD management strategies on clinical outcomes, value, and economic consequences for the entire health care system. The presentation format will be similar to a mock pharmacy and therapeutics committee meeting, featuring an expert panel including a leading neurologist in AD research and practice, a specialty pharmacy director, and managed care medical and pharmacy directors.

Program Manager
Steven Casebeer, MBA
Impact Education, LLC
info@impactedu.net
215-619-8812, extension 102

No Fee Registration: Click Here

Wednesday, March 29
6:00 AM – 8:00 AM
Non-Small Cell Lung Cancer (NSCLC) EGFR-Targeted Therapies: The Pharmacist’s Role in Tailoring Therapy and Improving Patient Outcomes

Provided by Creative Educational Concepts, Inc./CEC Oncology.
Supported by an independent educational grant from AstraZeneca.


Continuing education credit available for provided for pharmacists and physicians.

Program Description
Lung cancer is the most common cancer worldwide, as well as the leading cause of cancer death. Non small-cell lung cancer (NSCLC) accounts for more than 85% of lung cancer cases, and is typically associated with a poor prognosis (5-year survival rate of 17.4% at diagnosis.) Historically, advanced NSCLC has had a “one-size-fits-all” treatment paradigm, with platinum-based chemotherapy being the first-line choice. The discovery of NSCLC epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations sparked a movement towards the discovery of targetable oncogenes and the development of targeted therapies. Novel treatments have dramatically changed the NSCLC treatment landscape by impacting disease control, symptom palliation, and progression-free and overall survival rates in selected patients.

The objective of this educational activity is to provide evidence-based information on the latest developments in NSCLC, including updates on EGFR tyrosine kinase inhibitors (TKIs) and the importance of EGFR mutation testing, including molecular profiling using circulating tumor DNA (ctDNA) for tailoring therapy and improving patient outcomes. This activity will provide managed care pharmacists and physicians with an overview of the changing landscape of NSCLC treatment options and strategies to minimize financial burden while continuing to support the evolution of oncology healthcare reform.

Program Manager
Ashley C. Lilly, MHA
Creative Educational Concepts
alilly@ceconcepts.com
859-260-1717

No Fee Registration: Click Here

Wednesday, March 29
6:00 PM – 8:00 PM
Treatment Options, Clinical Pathways, and Collaborative Care: A Multiple Myeloma Update for Managed Care and Specialty Pharmacy

Provided by Impact Education, LLC and Postgraduate Institute for Medicine.
Supported by independent educational grants from Celgene Corporation and Takeda Oncology


Continuing education credit available for pharmacists and physicians.

Program Description
The management of multiple myeloma (MM) is a priority area for MCOs in order to optimize clinically- and economically-appropriate care for their members. As novel agents become available, treatment decision making is becoming more complex and MCOs and other payer organizations need to appropriately and effectively design benefits that optimize both cost-efficiency and patient outcomes. Guidance is needed for the target audience to implement current guidelines, utilize clinical pathways, design appropriate medical and pharmacy benefits, and implement effective specialty pharmacy management services.

This interactive program is designed to engage the faculty and audience to develop solutions for managed care professionals to implement within their own setting to improve outcomes for patients with MM. Multidisciplinary faculty will be utilized featuring a managed care medical director, a pharmacy director, and a hematology/oncology expert.

An innovative approach to the activity’s curriculum will feature a multiple myeloma patient testimonial and three faculty demonstrating the unique value each brings to the overall care of patients with MM through real world examples and case studies. By working together via data sharing and collaboration between payers, hematologists/oncologists, specialty pharmacy, and patients, on a more integrated approach, current barriers will be overcome, demonstrating value to all parties and motivating them to become further engaged.

Program Manager
Steven Casebeer, MBA
Impact Education, LLC
info@impactedu.net
215-619-8812, extension 102

No Fee Registration: Click Here

Wednesday, March 29
6:00 PM – 8:00 PM
The Managed Care Review Board™ – Examining the Impact of Cardiovascular Safety with Emerging Treatments for Type 2 Diabetes

Provided by Impact Education, LLC and Postgraduate Institute for Medicine.
Supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals Inc. and Lilly USA, LLC Alliance, Merck & Co., Inc., and Novo Nordisk, Inc.


Continuing education credit available for pharmacists and physicians.

Program Description
Prospective epidemiological and experimental studies have reported an association between suboptimal glycemic control as measured by an elevated glycated hemoglobin and both micro- and macrovascular complications. Individuals with type 2 diabetes mellitus (T2DM) have a 3-fold increase in cardiovascular mortality and a 2-fold increase in overall mortality compared to age-matched peers without T2DM. There is a clear need to develop therapeutic strategies to mitigate disease progression as well as reduce the cardiovascular disease burden.

Managed care pharmacists and other payer professionals require a thorough understanding of recent and emerging cardiovascular clinical trial evidence that can impact both clinical and economic outcomes for patients with T2DM. This symposium will enable plan decision-makers to more thoroughly evaluate T2DM agents under consideration for formulary inclusion as well as guide development of the plan T2DM benefit design and the T2DM treatment algorithm.

The educational format of The Managed Care Review Board™ will feature a multi-specialty, multi-professional faculty that collaborate, under the leadership of an Activity Chair, on the review of the clinical data, current guidelines, and economic data of a class of therapeutics. Similar to a mock pharmacy and therapeutics committee format, the program will include time for peer-to-peer discussion and debate among the diverse group of faculty members and the audience.

Program Manager
Steven Casebeer, MBA
Impact Education, LLC
info@impactedu.net
215-619-8812, extension 102

No Fee Registration: Click Here
THURSDAY, MARCH 30
Thursday, March 30
6:00 AM – 7:45 AM
The Specialty Pharmacy Review Board™ – Assessing the Evolving Value of Rheumatoid Arthritis Therapies

Provided by Impact Education, LLC and Medical Education Resources, Inc.
Supported by an independent educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding visit www.LillyGrantOffice.com.


Continuing education credit available for pharmacists and physicians.

Program Description
There is no cure for rheumatoid arthritis (RA), but new effective drugs are increasingly available to treat the disease and prevent deformed joints. Currently, the RA therapeutic pipeline is robust and includes agents that utilize novel mechanisms of action (MOAs) and various administration strategies (eg, oral, subcutaneous injection).

The Specialty Pharmacy Review Board format features a review of important, relevant therapeutic category information and features peer-to-peer exchange between a diverse group of managed care and clinical specialist faculty contributors. This interactive program is designed to engage the faculty and audience to develop solutions for specialty pharmacists and managed care professionals to implement within their own setting to improve outcomes for patients with RA. This approach supports managed care pharmacists by enhancing the results of their own health care organization's systematic literature reviews and analyses.

Program Manager
Steven Casebeer, MBA
Impact Education, LLC
info@impactedu.net
215-619-8812, extension 102

No Fee Registration: Click Here

Thursday, March 30
6:00 AM – 7:45 AM
An American Journal of Managed Care Symposium: Examining Treatment Advancements in Psoriasis and Psoriatic Arthritis

Provided by Pharmacy Times Continuing Education.
Supported by an independent educational grant from Lilly USA, LLC.


Continuing education credit available for pharmacists.

Program Description
Psoriasis and psoriatic arthritis are chronic, immune-mediated disorders that primarily affect the skin and joints, respectively. Clinical diagnosis of psoriasis relies primarily on physical exam, focusing on the skin, scalp, and nails, and on the patient’s medical history, including whether there is a family history of psoriasis. Psoriatic arthritis develops in 6% to 42% of patients with psoriasis and affects 0.1% to 0.25% of the general population. Almost one-third of patients with psoriasis are believed to be asymptomatic and living with undiagnosed psoriatic arthritis. This symposium will emphasize the need for pharmacists to proactively ask patients with psoriasis about joint pain and should utilize the CASPAR criteria to help detect early diagnosis and begin treatment.

Program Manager
Nicole Grassano
Pharmacy Times Continuing Education
ceinfo@pharmacytimes.com
1-800-597-6372

No Fee Registration: Click Here



The Academy of Managed Care Pharmacy (AMCP) does not oversee the content of these symposia and does not provide continuing pharmacy education credit for these educational activities. Opinions expressed during the Satellite Symposia are those of the faculty and are not necessarily a reflection of AMCP’s opinions, nor are they supported, sponsored, or endorsed by AMCP.



© 2017 Academy of Managed Care Pharmacy | 675 North Washington Street, Suite 220, Alexandria, VA 22314 | 703-684-2600 | webmaster@amcp.org